Karo Pharma AB has decided that the previously announced voluntary cash offer to acquire Weifa ASA will be extended by one week to 3 October 2017 at 16.30 (CEST)
As of today Karo Pharma has received acceptances under the Voluntary Offer for a total of 32 294 687 shares representing approximately 88.55 % of the total shares in Weifa on a fully diluted basis.
Except for the extension of the offer period, all other terms and conditions of the Voluntary Offer remain unchanged.
Karo Pharma maintains its right to further extend the offer period with one more week in case a minimum acceptance of at least 90% of the shares on a fully diluted basis has not been reached.
FOR FURTHER INFORMATION PLEASE CONTACT:
Peter Blom, CEO, 070-655 56 98 or email@example.com
ABOUT KARO PHARMA
Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.
The information in this report is such that Karo Pharma is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on September 26, 2017 at 17.30 p.m. CET. This press release is also available on www.newsroom.cision.com.
This news release contains certain forward-looking statements that are based on uncertainty, as they relate to events and depend on circumstances that will occur in the future and which, by their nature, may have an impact on results of operations and the financial condition of Karo Pharma and/or Weifa. Such forward-looking statements reflect our current expectations and are based on the information currently available. Neither Karo Pharma nor Weifa can give any assurance as to whether such forward looking statements will prove to be correct. These forward-looking statements include statements regarding the Offer, our expectations as to the launch of the Offer, including the terms of the Offer and expected timing, expected benefits of the Offer. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, among other things, satisfactions of conditions to the Offer and investor participation in the Offer.
The Offer will not be made in any jurisdiction in which making of the Offer would not be in compliance with the laws of such jurisdiction. This announcement does not in itself constitute an offer. The Offer will only be made on the basis of the Offer document and can only be accepted pursuant to the terms of such document.